Equity · Healthcare
FHTX
NASDAQFoghorn Therapeutics (FHTX)
This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.
- Market cap
- 299.8M USD
- P/E (TTM)
- 83.3
- Revenue, year to Dec 2025
- 30.9M USD
- EPS, diluted, year to Dec 2025
- −1.18 USD
- 52-week range
- 3.50 USD – 6.68 USD
- Avg volume
- 63.0K
as of Jul 17, 2026
Have Foghorn Therapeutics (FHTX) insiders bought or sold shares recently?
FHTX's newest Form 4 filing is dated 10 April 2026: none in the last 90 days.
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 10 Apr 2026 | GOTTSCHALK ADRIANChief Executive Officer | Gift | 118,416 | |
| 09 Apr 2026 | GOTTSCHALK ADRIANChief Executive Officer | Gift | 94,994 |
Which funds hold Foghorn Therapeutics (FHTX)?
6 of the 45 institutional funds we track reported a Foghorn Therapeutics position for the quarter ended 30 Sep 2026 — a combined 2.8M USD; the latest of those filings landed 16 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Renaissance Technologies | Held (±25%) | 432,339 | 1.5M USD | +14.4% |
| Citadel Advisors | Trimmed | 106,479 | 380K USD | −33.0% |
| Point72 Asset Management | New position | 106,201 | 379K USD | |
| Millennium Management | Added | 82,236 | 294K USD | +53.7% |
| AQR Capital Management | Trimmed | 37,375 | 133K USD | −43.6% |
| Two Sigma Investments | Added | 16,627 | 59K USD | +33.6% |
What has been filed or recorded for Foghorn Therapeutics (FHTX)?
The filings we hold for Foghorn Therapeutics, newest first: 2 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 28 Oct 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 28 Oct 2026 | Fails to deliver | Shares failed to deliver | 2,177 shares | 4K USD notional · 0.004% of shares out |
| 15 Oct 2026 | Fails to deliver | Shares failed to deliver | 1,514 shares | 3K USD notional · 0.003% of shares out |
| 30 Sep 2026 | Quarterly earnings | Q3 2026 reported | EPS 0.80 USD | Revenue $84M |
| 30 Sep 2026 | Financials | Total assets | 191.0M USD | at period end |
| 30 Sep 2026 | Financials | Total equity | −14.1M USD | at period end |
| 30 Jun 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.10 USD | Revenue $16M |
| 31 Mar 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.29 USD | Revenue $3M |
| 31 Dec 2025 | Annual report | FY 2025 reported | EPS −1.18 USD | Revenue $31M |
| 31 Dec 2025 | Financials | Revenue | 30.9M USD | fiscal year |
| 31 Dec 2025 | Financials | Net income | −74.3M USD | fiscal year |
| 31 Dec 2025 | Financials | Diluted EPS | −1.18 USD | fiscal year |
| 30 Sep 2025 | Quarterly earnings | Q3 2025 reported | EPS −0.25 USD | Revenue $8M |
| 30 Jun 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.28 USD | Revenue $8M |
| 31 Mar 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.30 USD | Revenue $6M |
| 31 Dec 2024 | Annual report | FY 2024 reported | EPS −1.58 USD | Revenue $23M |
What do people ask about Foghorn Therapeutics (FHTX)?
What is Foghorn Therapeutics’ market cap?299.8M
Foghorn Therapeutics is worth 299.8M USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.
What is Foghorn Therapeutics’ P/E ratio?83.3
Foghorn Therapeutics has a price-to-earnings ratio of 83.3, as of 17 Jul 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Foghorn Therapeutics’ revenue?30.9M
Foghorn Therapeutics reported revenue of 30.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings
Have Foghorn Therapeutics insiders bought or sold shares recently?
No Foghorn Therapeutics insider has filed a Form 4 in the last 90 days; the most recent filing we hold is dated 10 Apr 2026 (SEC Form 4). See Insiders
Which funds own Foghorn Therapeutics?6 of 45
6 of the 45 funds we track reported a Foghorn Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported positions were Renaissance Technologies, Citadel Advisors and Point72 Asset Management. See Funds
When did Foghorn Therapeutics last report earnings?0.80
Foghorn Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of 0.80 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close)
- TradingViewthe price chart widget, drawn by TradingView from their own data
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SECSEC fails-to-deliver (CNS) data
- SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings
- SEC filingAbout text: the company's latest annual report filed with the SEC (Business section), summarised in our own words